| [1] |
MESSINA JP, HUMPHREYS I, FLAXMAN A, et al. Global distribution and prevalence of hepatitis C virus genotypes[J]. Hepatology, 2015, 61( 1): 77- 87. DOI: 10.1002/hep.27259. |
| [2] |
TERGAST TL, BLACH S, TACKE F, et al. Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in Germany[J]. J Viral Hepat, 2022, 29( 7): 536- 542. DOI: 10.1111/jvh.13680. |
| [3] |
MADA PK, MALUS ME, PARVATHANENI A, et al. Impact of treatment with direct acting antiviral drugs on glycemic control in patients with hepatitis C and diabetes mellitus[J]. Int J Hepatol, 2020, 2020: 6438753. DOI: 10.1155/2020/6438753. |
| [4] |
MORALES AL, JUNGA Z, SINGLA MB, et al. Hepatitis C eradication with sofosbuvir leads to significant metabolic changes[J]. World J Hepatol, 2016, 8( 35): 1557- 1563. DOI: 10.4254/wjh.v8.i35.1557. |
| [5] |
POPESCU MS, FIRU DM, PĂDUREANU V, et al. Effects of achieving sustained virologic response after direct-acting antiviral agents on long-term liver fibrosis in diabetics vs. in non-diabetic patients with chronic hepatitis C infection[J]. Biomedicines, 2022, 10( 9): 2093. DOI: 10.3390/biomedicines10092093. |
| [6] |
KUMAR R, GARCÍA-COMPEÁN D, MAJI T. Hepatogenous diabetes: Knowledge, evidence, and skepticism[J]. World J Hepatol, 2022, 14( 7): 1291- 1306. DOI: 10.4254/wjh.v14.i7.1291. |
| [7] |
YAO LX, NIU B. Research progress of type 2 diabetes mellitus induced by hepatitis C virus infection[J]. Med Recapitul, 2022, 28( 6): 1186- 1192. DOI: 10.3969/j.issn.1006-2084.2022.06.026. |
| [8] |
XU LZ, ZUO WZ. Relationship between serum HCV-RNA load and FPG, FA, HbA1C in patients with chronic hepatitis C complicated with diabetes mellitus[J]. Shandong Med J, 2015, 55( 12): 80- 81. DOI: 10.3969/j.issn.1002-266X.2015.12.033. |
| [9] |
MAHMOUD B, ABDEL MONEIM A, MABROUK D. The impact of HCV eradication on hyperglycemia, insulin resistance, cytokine production, and insulin receptor substrate-1 and 2 expression in patients with HCV infection[J]. Clin Exp Med, 2022, 22( 4): 583- 593. DOI: 10.1007/s10238-021-00773-1. |
| [10] |
ABDEL MONEIM A, SULEIMAN HA, MAHMOUD B, et al. Viral clearance ameliorates hematological and inflammatory markers among diabetic patients infected with hepatitis C genotype 4[J]. Clin Exp Med, 2020, 20( 2): 231- 240. DOI: 10.1007/s10238-019-00605-3. |
| [11] |
LAPUMNUAYPOL K, PISARCIK D, PUTTHAPIBAN P, et al. Direct-acting antiviral agents decrease haemoglobin A1c level in patients with diabetes infected with hepatitis C virus: A systematic review& meta-analysis[J]. Indian J Med Res, 2020, 152( 6): 562- 567. DOI: 10.4103/ijmr.IJMR_1088_18. |
| [12] |
WEIDNER P, BOETTCHE D, ZIMMERER T, et al. Impact of direct acting antiviral(DAA) treatment on glucose metabolism and reduction of pre-diabetes in patients with chronic hepatitis C[J]. J Gastrointestin Liver Dis, 2018, 27( 3): 281- 289. DOI: 10.15403/jgld.2014.1121.273.daa. |
| [13] |
CACCIOLA I, RUSSO G, FILOMIA R, et al. Over time evaluation of glycaemic control in direct-acting antiviral-treated hepatitis C virus/diabetic individuals with chronic hepatitis or with cirrhosis[J]. Liver Int, 2021, 41( 9): 2059- 2067. DOI: 10.1111/liv.14905. |
| [14] |
DOYLE MA, GALANAKIS C, MULVIHILL E, et al. Hepatitis C direct acting antivirals and ribavirin modify lipid but not glucose parameters[J]. Cells, 2019, 8( 3): 252. DOI: 10.3390/cells8030252. |
| [15] |
DAWOOD AA, NOOH MZ, ELGAMAL AA. Factors associated with improved glycemic control by direct-acting antiviral agent treatment in Egyptian type 2 diabetes mellitus patients with chronic hepatitis C genotype 4[J]. Diabetes Metab J, 2017, 41( 4): 316- 321. DOI: 10.4093/dmj.2017.41.4.316. |
| [16] |
GRAF C, WELZEL T, BOGDANOU D, et al. Hepatitis C clearance by direct-acting antivirals impacts glucose and lipid homeostasis[J]. J Clin Med, 2020, 9( 9): 2702. DOI: 10.3390/jcm9092702. |
| [17] |
GILAD A, FRICKER ZP, HSIEH A, et al. Sustained improvement in type 2 diabetes mellitus is common after treatment of hepatitis C virus with direct-acting antiviral therapy[J]. J Clin Gastroenterol, 2019, 53( 8): 616- 620. DOI: 10.1097/MCG.0000000000001168. |
| [18] |
CIANCIO A, BOSIO R, BO S, et al. Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents[J]. J Med Virol, 2018, 90( 2): 320- 327. DOI: 10.1002/jmv.24954. |
| [19] |
LI J, GORDON SC, RUPP LB, et al. Sustained virological response to hepatitis C treatment decreases the incidence of complications associated with type 2 diabetes[J]. Aliment Pharmacol Ther, 2019, 49( 5): 599- 608. DOI: 10.1111/apt.15102. |
| [20] |
KOENIG LR, ROSENBLATT R, PATEL RM, et al. Comorbid hepatitis C does not modulate prevalence or severity of diabetic retinopathy[J]. Clin Ophthalmol, 2019, 13: 1681- 1687. DOI: 10.2147/OPTH.S209274. |
| [21] |
LI J, GORDON SC, RUPP LB, et al. Sustained virological response does not improve long-term glycaemic control in patients with type 2 diabetes and chronic hepatitis C[J]. Liver Int, 2019, 39( 6): 1027- 1032. DOI: 10.1111/liv.14031. |
| [22] |
TRIFAN A, STRATINA E, ROTARU A, et al. Changes in liver steatosis using controlled attenuation parameter among patients with chronic hepatitis C infection treated with direct-acting antivirals therapy who achieved sustained virological response[J]. Diagnostics(Basel), 2022, 12( 3): 702. DOI: 10.3390/diagnostics12030702. |
| [23] |
OGASAWARA N, KOBAYASHI M, AKUTA N, et al. Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b[J]. J Med Virol, 2018, 90( 2): 313- 319. DOI: 10.1002/jmv.24950. |
| [24] |
ROUT G, NAYAK B, PATEL AH, et al. Therapy with oral directly acting agents in hepatitis C infection is associated with reduction in fibrosis and increase in hepatic steatosis on transient elastography[J]. J Clin Exp Hepatol, 2019, 9( 2): 207- 214. DOI: 10.1016/j.jceh.2018.06.009. |
| [25] |
CASAS-DEZA D, MARTÍNEZ-SAPIÑA A, ESPINA S, et al. Evaluation of cardiovascular risk factors after hepatitis C virus eradication with direct-acting antivirals in a cohort of treatment-Naïve patients without history of cardiovascular disease[J]. J Clin Med, 2022, 11( 14): 4049. DOI: 10.3390/jcm11144049. |
| [26] |
HUANG CF, DAI CY, YEH ML, et al. Cure or curd: Modification of lipid profiles and cardio-cerebrovascular events after hepatitis C virus eradication[J]. Kaohsiung J Med Sci, 2020, 36( 11): 920- 928. DOI: 10.1002/kjm2.12275. |
| [27] |
RAMADAN MS, BOCCIA F, MORETTO SM, et al. Cardiovascular risk in patients with chronic hepatitis C treated with direct acting antivirals[J]. J Clin Med, 2022, 11( 19): 5781. DOI: 10.3390/jcm11195781. |
| [28] |
KAWAGISHI N, SUDA G, NAKAMURA A, et al. Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis[J]. PLoS One, 2018, 13( 12): e0209615. DOI: 10.1371/journal.pone.0209615. |
| [29] |
SCHMIDT FP, ZIMMERMANN T, WENZ T, et al. Interferon- and ribavirin-free therapy with new direct acting antivirals(DAA) for chronic hepatitis C improves vascular endothelial function[J]. Int J Cardiol, 2018, 271: 296- 300. DOI: 10.1016/j.ijcard.2018.04.058. |
| [30] |
FREEKH DA, HELMY MW, SAID M, et al. The effect of direct acting antiviral agents on vascular endothelial function in Egyptian patients with chronic hepatitis C virus infection[J]. Saudi Pharm J, 2021, 29( 10): 1120- 1128. DOI: 10.1016/j.jsps.2021.08.006. |
| [31] |
MUÑOZ-HERNÁNDEZ R, AMPUERO J, MILLÁN R, et al. Hepatitis C virus clearance by direct-acting antivirals agents improves endothelial dysfunction and subclinical atherosclerosis: HEPCAR study[J]. Clin Transl Gastroenterol, 2020, 11( 8): e00203. DOI: 10.14309/ctg.0000000000000203. |
| [32] |
DI MINNO MND, AMBROSINO P, BUONOMO AR, et al. Direct-acting antivirals improve endothelial function in patients with chronic hepatitis: A prospective cohort study[J]. Intern Emerg Med, 2020, 15( 2): 263- 271. DOI: 10.1007/s11739-019-02163-8. |
| [33] |
PETTA S, ADINOLFI LE, FRACANZANI AL, et al. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis[J]. J Hepatol, 2018, 69( 1): 18- 24. DOI: 10.1016/j.jhep.2018.02.015. |
| [34] |
REVUELTO ARTIGAS T, BETRIU BARS À, ZARAGOZA VELASCO N, et al. Antiviral treatment does not improve subclinical atheromatosis in patients with chronic hepatitis caused by hepatitis C virus[J]. Gastroenterol Hepatol, 2019, 42( 6): 362- 371. DOI: 10.1016/j.gastrohep.2019.02.002. |
| [35] |
CALVARUSO V, PETTA S, CACCIOLA I, et al. Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-HCV cohort[J]. J Viral Hepat, 2021, 28( 8): 1190- 1199. DOI: 10.1111/jvh.13523. |
| [36] |
YANG YH, CHIANG HJ, YIP HK, et al. Risk of new-onset atrial fibrillation among Asian chronic hepatitis C virus carriers: A nationwide population-based cohort study[J]. J Am Heart Assoc, 2019, 8( 22): e012914. DOI: 10.1161/JAHA.119.012914. |
| [37] |
POL S, PARLATI L, JADOUL M. Hepatitis C virus and the kidney[J]. Nat Rev Nephrol, 2019, 15( 2): 73- 86. DOI: 10.1038/s41581-018-0081-8. |
| [38] |
MA Y, HUANG Z, JIAN Z, et al. The association between hepatitis C virus infection and renal cell cancer, prostate cancer, and bladder cancer: A systematic review and meta-analysis[J]. Sci Rep, 2021, 11: 10833. DOI: 10.1038/s41598-021-90404-2. |
| [39] |
TANG MZ, ZHANG KQ. Status of clinical research in HCV-negative recipients undergoing kidney transplantation from HCV-positive renal allografts[J]. Ogran Transplant, 2023, 14( 2): 235- 240. DOI: 10.3969/j.issn.1674-7445.2023.02.009. |
| [40] |
RIDRUEJO E, GARCIA-AGUDO R, MENDIZABAL M, et al. Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease[J]. Nefrologia(Engl Ed), 2020, 40( 1): 46- 52. DOI: 10.1016/j.nefro.2019.03.013. |
| [41] |
NEVOLA R, RINALDI L, ZENI L, et al. Metabolic and renal changes in patients with chronic hepatitis C infection after hepatitis C virus clearance by direct-acting antivirals[J]. JGH Open, 2020, 4( 4): 713- 721. DOI: 10.1002/jgh3.12324. |
| [42] |
VILLANI R, ROMANO AD, SANGINETO M, et al. Direct-acting antivirals improve kidney function in diabetic patients with HCV infection and chronic kidney disease[J]. Intern Emerg Med, 2021, 16( 5): 1239- 1245. DOI: 10.1007/s11739-020-02628-1. |
| [43] |
de CASTRO GLC, da SILVA GRAÇA AMORAS E, ARAÚJO MS, et al. High prevalence of antinuclear antibodies in patients with chronic hepatitis C virus infection[J]. Eur J Med Res, 2022, 27( 1): 180. DOI: 10.1186/s40001-022-00809-6. |
| [44] |
ROMANO C, TORTORELLA O, DALLA MORA L, et al. Prevalence and outcome of serum autoantibodies in chronic hepatitis C patients undergoing direct-acting antiviral treatment[J]. Front Immunol, 2022, 13: 882064. DOI: 10.3389/fimmu.2022.882064. |
| [45] |
BONACCI M, LENS S, MARIÑO Z, et al. Long-term outcomes of patients with HCV-associated cryoglobulinemic vasculitis after virologic cure[J]. Gastroenterology, 2018, 155( 2): 311- 315. DOI: 10.1053/j.gastro.2018.04.024. |
| [46] |
TERZIROLI BERETTA-PICCOLI B, DI BARTOLOMEO C, DELEONARDI G, et al. Autoimmune liver serology before and after successful treatment of chronic hepatitis C by direct acting antiviral agents[J]. J Autoimmun, 2019, 102: 89- 95. DOI: 10.1016/j.jaut.2019.04.019. |
| [47] |
FACCIOLI J, NARDELLI S, GIOIA S, et al. Neurological and psychiatric effects of hepatitis C virus infection[J]. World J Gastroenterol, 2021, 27( 29): 4846- 4861. DOI: 10.3748/wjg.v27.i29.4846. |
| [48] |
KLEEFELD F, HELLER S, INGILIZ P, et al. Interferon-free therapy in hepatitis C virus(HCV) monoinfected and HCV/HIV coinfected patients: Effect on cognitive function, fatigue, and mental health[J]. J Neurovirol, 2018, 24( 5): 557- 569. DOI: 10.1007/s13365-018-0647-z. |
DownLoad: